

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 077 063 A2**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

**21.02.2001 Bulletin 2001/08**

(51) Int Cl.7: **A61K 7/48**

(21) Application number: **00306352.6**

(22) Date of filing: **26.07.2000**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**

Designated Extension States:

**AL LT LV MK RO SI**

(30) Priority: **27.07.1999 US 361429**

(71) Applicant: **JOHNSON & JOHNSON CONSUMER  
COMPANIES, INC.**

**Skillman, NJ 08558 (US)**

(72) Inventors:

- **Seiberg, Miri**  
**Princeton, NJ 08540 (US)**
- **Shapiro, Stanley S.**  
**Livingston, NJ 07039 (US)**

(74) Representative: **Fisher, Adrian John**

**CARPMAELS & RANSFORD**  
**43 Bloomsbury Square**  
**London WC1A 2RA (GB)**

(54) **Methods for treating skin pigmentation**

(57) This invention relates to methods and compositions for bringing about changes in skin pigmentation. More particularly, this invention relates to compounds

which affect melanogenesis and can be used as depigmenting agents or as agents for darkening skin utilizing the PAR-2 pathway.

Best Available Copy

**EP 1 077 063 A2**

**Description****Background**

[0001] This is a continuation-in-part application of U.S. Patent Application Serial No. 09/110,409 (Attorney Docket No. JBP 430), which is hereby incorporated herein by reference.

**1. Field of the Invention**

[0002] This invention is related to methods and compositions for bringing about skin pigmentation and/or for causing skin depigmentation. More particularly, this invention relates to compounds which affect melanogenesis and can be used as depigmenting agents or as agents for darkening skin.

**2. Background of the Invention**

[0003] Skin coloring has been of concern to human beings for many years. In particular, the ability to remove hyperpigmentation, such as found in age spots, freckles or aging skin generally, is of interest to individuals desiring a uniform complexion. In certain areas of the world, general body whitening is desirable. There are also hypopigmentation and hyperpigmentation disorders that are desirable to treat. Likewise, the ability to generate a tanned appearance without incurring photodamage due to solar radiation is important to many individuals. There have been many methods proposed to accomplish depigmentation, as well as to accomplish darkening of the skin. For example, kojic acid, hydroquinone, retinoids and other chemical compounds have been used for depigmentation. Dihydroxyacetone and like chemical compounds have been utilized for their ability to "tan" the skin without exposure to the sun.

[0004] Many of these previous solutions have not been found acceptable. There is often a distinct line of demarcation between the areas of skin to which such previous compositions have been applied. Therefore, precise application of all these compounds is necessary in order to achieve the desired result. Many of these compounds have been found to be quite irritating to the skin and therefore undesirable for use.

[0005] The understanding of the chemical and enzymatic basis of melanogenesis is heavily documented. Melanocytes migrate from the embryonal neural crest into the skin to produce secretory granules, melanosomes, which produce melanin. Melanogenesis occurs within the melanosome, and the melanin is later distributed to keratinocytes via the melanocyte dendrites. The key enzyme in melanogenesis is tyrosinase, which initiates a cascade of reactions which convert tyrosine to the biopolymer melanin. Two tyrosinase-related proteins (TRP's) are known, TRP-1 and TRP-2. These proteins share with tyrosinase about 40% homology and have catalytic activities as well as regulatory roles in melanogenesis. TRP-1 is the most abundant glycoprotein in melanocytes.

[0006] In spite of the fact that the chemical and enzymatic basis of melanogenesis is well-documented, its regulation at the cellular level is only partially understood. Tyrosinase and the TRP's share structural and biological properties with the lysosomal-associated membrane protein (LAMP) gene family, therefore their targeting to the melanosomal membrane might induce their activation. A phosphorylation/dephosphorylation reaction at the cytoplasmic tails of these proteins could be involved in the regulation of melanogenesis. The beta isoform of the Protein Kinase C (PKC) family has been shown to regulate human melanogenesis through tyrosinase activation. Gene expression of tyrosinase, TRP-1 and TRP-2 is coordinated. All three enzymes are expressed in human epidermis. In melanocytes co-cultured with keratinocytes, these transcripts are expressed at a ratio of 45:45:10, respectively. In melanocytes cultured alone, only TRP-1 transcripts are present, indicating that a keratinocyte-derived signal is involved in the coordinate expression of these genes. The regulation of keratinocyte-melanocyte interactions and the mechanism of melanosome transfer into keratinocytes are not yet understood.

[0007] The Protease-activated receptor-2 (PAR-2) is a seven transmembrane G-protein-coupled receptor, that is related to, but distinct from the thrombin receptors (TR, also named PAR-1, and PAR-3) in its sequence. Both receptors are activated proteolytically by an arginine-serine cleavage at the extracellular domain. The newly created N-termini then activate these receptors as tethered ligands. Both receptors could be activated by trypsin, but only the TRs are activated by thrombin. Only PAR-2 is activated by mast cell tryptase. Both receptors could also be activated by the peptides that correspond to their new N-termini, independent of receptor cleavage. SLIGRL, the mouse PAR-2 activating peptide, is equipotent in the activation of the human receptor. While the function of the TR is well documented, the biology of the PAR-2 has not yet been fully identified. A role for PAR-2 activation in the inhibition of keratinocyte growth and differentiation has been recently described (Derian et al., "Differential Regulation of Human Keratinocyte Growth and Differentiation by a Novel Family of Protease-activate Receptors", *Cell Growth & Differentiation*, Vol. 8, pp. 743-749, July 1997).

## Summary of the Invention

[0008] In accordance with this invention, we have found a method for affecting changes in mammalian skin pigmentation comprising topically applying to the skin of a mammal a compound which affects the PAR-2 pathway. The compositions of this invention may contain one or more compounds that act as trypsin, as trypsinase, as serine protease or as PAR-2 agonists, for increase in pigmentation. Alternatively, they may contain one or more compounds that act as serine protease inhibitors, trypsin inhibitors, thrombin inhibitors, trypsinase inhibitors, as PAR-2 pathway inhibitors or as a PAR-2 antagonist for decrease in pigmentation, or "depigmentation".

[0009] As used herein, "mammal" means any member "of the higher vertebrate animals comprising the class "Mammalia", as defined in Webster's Medical Desk Dictionary 407(1986), and includes but is not limited to humans. As used herein, "receptor" shall include both intracellular and extracellular receptors and shall mean those molecules capable of receiving and transducing a signal. The term PAR-2 refers to the protease-activated receptor-2 or a related protease activated receptor. The Protease-activated receptor-2 (hereinafter, "PAR-2") is a serine-protease activated receptor that is expressed in numerous tissues, including keratinocytes and fibroblasts. The thrombin receptor (also named PAR-1, hereinafter, "TR") is a serine-protease activated receptor that is expressed in numerous tissues, including keratinocytes. The biological roles of PAR-2 and TR in skin are not entirely known. However, we have found that interactions between keratinocytes and melanocytes, via the PAR-2 pathway, affect melanogenesis. We have found that thrombin inhibitors, and/or trypsinase inhibitors, and/or trypsin inhibitors and PAR-2 antagonists can be used as depigmenting agents without irritation of the skin. PAR-2 agonists and serine proteases such as trypsin and trypsinase can be used as darkening agents. Furthermore, PAR-2 could be useful as a target for whitening and darkening agents.

[0010] We have further discovered that BBI, a Bowman-Birk type inhibitor, may also be used as an active depigmenting agent. Soybean-derived extracts and mixtures that were suggested in U.S. Patent Application Serial No. 09/110,409 as depigmenting agents contain both STI and BBI. We have now found that BBI alone is effective to depigment skin. BBI may be used in all the formulations and compositions set forth in the parent application in the same range of concentration as STI.

## Brief Description of the Drawings

[0011] Figure 1 shows epidermal equivalents containing melanocytes of an African-American donor. Treatment with BBI reduces pigment deposition in these equivalents, as demonstrated by top view of the equivalents, with no staining.

[0012] Figure 2 shows epidermal equivalents containing melanocytes of an African-American donor. Treatment with BBI reduces pigment deposition in these equivalents, as demonstrated by Fontana-Mason staining of histological sections of these equivalents.

[0013] Figure 3 shows epidermal equivalents containing melanocytes of an African-American donor. Treatment with increasing concentrations of BBI reduces pigment deposition in these equivalents in a dose-dependent fashion, as demonstrated by Fontana-Mason staining of histological sections of these equivalents.


[0014] Figure 4 is a graph quantifying the percent of inhibition of pigment deposition following BBI treatment.

[0015] Figure 5 shows F&M stained histological sections from swine skin treated with BBI and STI. Melanin deposition in the swine skin is dramatically reduced following BBI or STI treatment.

[0016] Figure 6 is a graph of computerized image analysis of pigment deposition in skin sections such as those demonstrated in Figure 5. The graph quantifies the percent of inhibition of pigment deposition in the swine skin following BBI or STI treatment.

## Detailed Description of the Preferred Embodiments

[0017] We have discovered that trypsin, trypsinase and PAR-2 agonists can be used to increase pigmentation and that trypsin inhibitors, and/or trypsinase inhibitors, and/or thrombin inhibitors and PAR-2 antagonists act to decrease pigmentation in mammalian skin. In our opinion, some of the compounds described in U.S. Patent No. 5,523,308, which is hereby incorporated herein by reference, and behave as thrombin and/or trypsin and/or trypsinase inhibitors, will be useful in methods of this invention. Some of these compounds are also described in Costanzo, et al., "Potent Thrombin Inhibitors That Probe the S<sub>1</sub>' Subsite: Tripeptide Transition State Analogues Based on a Heterocycle-Activated Carbonyl Group", J. Med. Chem., 1996, Vol. 39, pp. 3039-3043 and have the following structural formula:



wherein:

A is selected from the group consisting of C<sub>1-8</sub>alkyl, carboxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxycarbonylC<sub>1-4</sub>alkyl, phenylC<sub>1-4</sub>alkyl, substituted phenylC<sub>1-4</sub>alkyl (where the phenyl substituents are independently selected from one or more of, C<sub>1-4</sub> alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub> alkoxycarbonyl), formyl, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-2</sub>alkylcarbonyl, phenylC<sub>1-4</sub>alkoxycarbonyl, C3-7cycloalkylcarbonyl, phenylcarbonyl, substituted phenylcarbonyl (where the phenyl substituents are independently selected from one or more of, C<sub>1-4</sub>alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino carboxy or C<sub>1-4</sub> alkoxycarbonyl), C<sub>1-4</sub>alkylsulfonyl, C<sub>1-4</sub>alkoxysulfonyl, perfluoroC<sub>1-4</sub>alkyl-sulfonyl, phenylsulfonyl, substituted phenylsulfonyl (where the phenyl substituents are independently selected from one or more of, C<sub>1-4</sub>alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub> alkoxycarbonyl), 10-camphorsulfonyl, phenylC<sub>1-4</sub>alkylsulfonyl, substituted phenylC<sub>1-4</sub>alkylsulfonyl, C<sub>1-4</sub>alkylsulfinyl, perfluoroC<sub>1-4</sub>alkylsulfinyl, phenylsulfinyl, substituted phenylsulfinyl (where the phenyl substituents are independently selected from one or more of, C<sub>1-4</sub>alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub>alkoxycarbonyl), phenylC<sub>1-4</sub>alkylsulfinyl, substituted phenylC<sub>1-4</sub>alkylsulfinyl, 1-naphthylsulfonyl, 2-naphthylsulfonyl or substituted naphthylsulfonyl (where the naphthyl substituents are independently selected from one or more of, C<sub>1-4</sub>alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino, carboxy or C<sub>1-4</sub>alkoxy-carbonyl), 1-naphthylsulfinyl, 2-naphthylsulfinyl or substituted naphthylsulfinyl (where the naphthyl substituents are independently selected from one or more of, C<sub>1-4</sub>alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub>alkoxycarbonyl);

a D or L amino acid which is coupled as its carboxy terminus to the nitrogen depicted in formula I and is selected from the group consisting of alanine, asparagine, 2-azetidinecarboxylic acid, glycine, N-C<sub>1-8</sub>alkylglycine, proline, 1-amino-1-cycloC<sub>3-8</sub>alkylcarboxylic acid, thiazolidine-4-carboxylic acid, 5,5-dimethylthiazolidine-4-carboxylic acid, oxadoline-4-carboxylic acid, pipecolinic acid, valine, methionine, cysteine, serine, threonine, norleucine, leucine, tert-leucine, isoleucine, phenylalanine, 1-naphthylalanine, 2-naphthylalanine, 2-thienylalanine, 3-thienylalanine, [1,2,3,4]-tetrahydroisoquinoline-1-carboxylic acid and 1,2,3,4]-tetrahydroisoquinoline-2-carboxylic acid

where the amino terminus of said amino acid is connected to a member selected from the group consisting of C<sub>1-4</sub>alkyl, tetrazol-5yl-C<sub>1-2</sub>alkyl, carboxylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxycarbonylC<sub>1-4</sub>alkyl, phenylC<sub>1-4</sub>alkyl, substituted phenyl C<sub>1-4</sub> alkyl (where the phenyl substituents are independently selected from one or more of, C<sub>1-4</sub>alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub>alkoxycarbonyl), 1,1-diphenylC<sub>1-4</sub>alkyl, 3-phenyl-2-hydroxypropionyl, 2,2-diphenyl-1-hydroxyethylcarbonyl, [1,2,3,4]-tetrahydroisoquinoline-1-carbonyl, [1,2,3,4]-tetrahydroisoquinoline-3-carbonyl, 1-methylamino-1-cyclohexanecarbonyl, 1-hydroxy-1-cyclohexanecarbonyl, 1-hydroxy-1-phenyl-lacetyl, 1-cyclohexyl-1-hydroxyacetyl, 3-phenyl-2-hydroxypropionyl, 3,3-diphenyl-2-hydroxypropionyl, 3-cyclohexyl-2-hydroxypropionyl, formyl, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-12</sub>alkylcarbonyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylcarbonyl, phenylC<sub>1-4</sub>alkylcarbonyl, substituted phenylC<sub>1-4</sub>alkylcarbonyl (where the phenyl substituents are independently selected from one or more of, C<sub>1-4</sub>alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo amido, nitro amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub>alkoxycarbonyl), 1,1-diphenylC<sub>1-4</sub>alkylcarbonyl, substituted 1,1-diphenylC<sub>1-4</sub>alkylcarbonyl (where the phenyl substituents are independently selected from one or more of, C<sub>1-4</sub>alkyl, perfluoro C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub> alkoxycarbonyl), perfluoroC<sub>1-4</sub>alkylsulfonyl, C<sub>1-4</sub>alkylsulfonyl, C<sub>1-4</sub>alkoxysulfonyl, phenylsulfonyl, substituted phenylsulfonyl (where the phenyl substituents are independently selected from one or more of, C<sub>1-4</sub>alkyl, perfluoro C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub>alkoxycarbonyl), 10-camphorsulfonyl, phenylC<sub>1-4</sub>alkylsulfonyl, substituted phenylC<sub>1-4</sub>alkylsulfonyl, perfluoroC<sub>1-4</sub>alkylsulfinyl, C<sub>1-4</sub>alkylsulfinyl, phenylsulfinyl, substituted phenylsulfinyl (where the phenyl substituents are independently selected from one or more of, C<sub>1-4</sub>alkyl, perfluoro C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub>alkoxycarbonyl), 1-naphthylsulfonyl, 2-naphthylsulfonyl, substituted naphthylsulfonyl (where the naphthyl substituents are independently selected from one or more of, C<sub>1-4</sub>alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino,

C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub>alkoxycarbonyl), 1-naphthylsulfinyl, 2-naphthylsulfinyl, and substituted naphthylsulfinyl (where the naphthyl substituents are independently selected from one or more of, C<sub>1-4</sub>alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>10-14</sub>dialkylamino, carboxy or C<sub>1-4</sub>alkoxycarbonyl):

or a poly peptide comprised of two amino acids,


where the first amino acid is a D or L amino acid, bound via its carboxy terminus to the nitrogen depicted in Formula I and is selected from the group consisting of glycine, N-C<sub>1-4</sub>alkylglycine, alanine, 2-azetidinecarboxylic acid, proline, thiazolidine-4-carboxylic acid, 5,5-dimethylthiazolidine-4-carboxylic acid, oxazolidine-4-carboxylic acid, 1-amino-1-cycloC<sub>3-8</sub>alkylcarboxylic acid, 3-hydroxyproline, 4-hydroxyproline, 3-(C<sub>1-4</sub>alkoxy)proline, 4-(C<sub>1-4</sub>alkoxy)proline, 3,4-dehydroproline, 2,2-dimethyl-4-thiazolidine carboxylic acid, 2,2-dimethyl-4-oxazolidine carboxylic acid, pipercolinic acid, valine, methionine, cysteine, asparagine, serine, threonine, leucine, tert-leucine, isoleucine, phenylalanine, 1-naphthalanine, 2-naphthalanine, 2-thienylalanine, 3-thienylalanine, [1,2,3,4]-tetrahydroisoquinoline-2-carboxylic acid, aspartic acid-4-C<sub>1-4</sub>alkyl ester and glutamic acid-5-C<sub>1-4</sub>alkyl ester

and the second D or L amino acid, is bound to the amino terminus of said first amino acid, and is selected from the group consisting of phenylalanine, 4-benzoylphenylalanine, 4-carboxyphenylalanine, 4-(Carboxy C<sub>1-2</sub>alkyl)phenylalanine, substituted phenylalanine (where the phenyl substituents are independently selected from one or more of C<sub>1-4</sub>alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub>alkoxycarbonyl), 3-benzothienylalanine, 4-biphenylalanine, homophenylalanine, octahydroindole-2-carboxylic acid, 2-pyridylalanine, 3-pyridylalanine, 4-thiazolylalanine, 2-thienylalanine, 3-(3-benzothienyl)alanine, 3-thienylalanine, tryptophan, tyrosine, asparagine, 3-tri-C<sub>1-4</sub>alkylsilylalanine, cyclohexylglycine, diphenylglycine, phenylglycine, methionine sulfoxide, methionine sulfone, 2,2-dicyclohexylalanine, 2-(1-naphthylalanine), 2-(2-naphthylalanine); phenyl substituted phenylalanine (where the substituents are selected from C<sub>1-4</sub>alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub>alkoxycarbonyl), aspartic acid, aspartic acid-4-C<sub>1-4</sub>alkyl, perfluoroc<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub>alkoxycarbonyl), aspartic acid, aspartic acid-4-C<sub>1-4</sub>alkyl ester glutamic acid, glutamic acid-5-C<sub>1-4</sub>alkyl ester, cycloC<sub>3-8</sub>alkylalanine, substituted cycloC<sub>3-8</sub>alkylalanine (where the ring substituents are carboxy, C<sub>1-4</sub>alkyl ester, cycloC<sub>3-8</sub>alkylalanine, substituted cycloC<sub>3-8</sub>alkylalanine (where the ring substituents are carboxy, C<sub>1-4</sub>alkylcarboxy, C<sub>1-4</sub>alkoxycarbonyl or aminocarbonyl), 2,2-diphenylalanine and all alpha-C<sub>1-5</sub>alkyl of all amino acid derivatives thereof, where the amino terminus

of said second amino acid is unsubstituted or monosubstituted with a member of the group consisting of formyl, C<sub>1-12</sub>alkyl, tetrazol-5-ylC<sub>1-2</sub>alkyl, carboxyC<sub>1-8</sub>alkyl, carboalkoxyC<sub>1-4</sub>alkyl, phenyl C<sub>1-4</sub>alkyl, substituted phenylC<sub>1-4</sub>alkyl (where the phenyl substituents are independently selected from one or more of, C<sub>1-4</sub>alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub>alkoxycarbonyl), 1,1-diphenylC<sub>1-4</sub>alkyl, C<sub>1-6</sub>alkoxycarbonyl, phenylC<sub>1-6</sub>alkoxycarbonyl, C<sub>1-2</sub>alkylcarbonyl, perfluoroC<sub>1-4</sub>alkylC<sub>1-4</sub>alkoxycarbonyl, phenylC<sub>1-4</sub>alkylcarbonyl, substituted phenylC<sub>1-4</sub>alkylcarbonyl (where the phenyl substituents are independently selected from one or more of C<sub>1-4</sub>alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub>alkoxycarbonyl), 1,1-diphenylC<sub>1-4</sub>alkyl perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxycarbonyl), 10-camphorsulfonyl, phenylC<sub>1-4</sub>alkylsulfonyl, substituted phenylC<sub>1-4</sub>alkylsulfonyl, C<sub>1-4</sub>alkylsulfonyl, perfluoro C<sub>1-4</sub>alkylsulfonyl, phenylsulfonyl, substituted phenylsulfonyl (where the phenyl substituents are independently selected from one or more of, C<sub>1-4</sub>alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub>alkoxycarbonyl), phenylC<sub>1-4</sub>alkylsulfonyl, substituted phenylC<sub>1-4</sub>alkylsulfonyl 1-naphthylsulfonyl, 2-naphthylsulfonyl, substituted naphthylsulfonyl (where the naphthyl substituent is selected from C<sub>1-4</sub>alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub>alkoxycarbonyl), 1-naphthylsulfonyl, 2-naphthylsulfonyl and substituted naphthyl-sulfonyl (where the naphthyl substituent is selected from C<sub>1-4</sub>alkyl, perfluoroC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy or C<sub>1-4</sub>alkoxycarbonyl); R<sub>1</sub> is selected from the group consisting of hydrogen and alkyl; R<sub>2</sub> is selected from the group consisting of aminoC<sub>2-5</sub>alkyl, guanidinoC<sub>2-5</sub>alkyl, C<sub>1-4</sub>alkylguanidinoC<sub>2-5</sub>alkyl, diC<sub>1-4</sub>alkylguanidinoC<sub>2-5</sub>alkyl, amidinoC<sub>2-5</sub>alkyl, C<sub>1-4</sub>alkylamidinoC<sub>2-5</sub>alkyl, diC<sub>1-4</sub>alkylamidinoC<sub>2-5</sub>alkyl, C<sub>1-3</sub>alkoxyC<sub>2-5</sub>alkyl, phenyl, substituted phenyl (where the substituents are independently selected from one or more of amino, amidino, guanidino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, halogen, perfluoro C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyl, C<sub>1-3</sub>alkoxy or nitro), benzyl, phenyl substituted benzyl (where the substituents are independently selected from one or more of, amino, amidino, guanidino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, halogen, perfluoro C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyl, C<sub>1-3</sub>alkoxy or nitro), hydroxyC<sub>2-5</sub>alkyl, C<sub>1-5</sub>alkylaminoC<sub>2-5</sub>alkyl, C<sub>1-5</sub>dialkylaminoC<sub>2-5</sub>alkyl, 4-aminocyclohexylC<sub>0-2</sub> and C<sub>1-5</sub>alkyl;

p is 0 or 1;

B is



where  $n$  is 0-3,  $R_3$  is H or C1-5alkyl and the carbonyl moiety of B is bound to E; E is a heterocycle selected from the group consisting of oxazolin-2-yl, oxazol-2-yl, thiazol-2-yl, thiazol-5-yl, thiazol-4-yl, thiazolin-2-yl, imidazol-2-yl, 4-oxo-2-quinoxalin-2-yl, 2-pyridyl, 3-pyridyl benzo[b]thiophen-2-yl, triazol-4-yl triazol-6-yl, pyrazol-2-yl, 4,5,6,7-tetrahydrobenzothiazol-2-yl, naphtho[2,1-d]thiazol-2-yl, naphtho[1,2-d]thiazol-2-yl quinoxalin-2-yl, isoquinolin-1-yl, isoquinolin-3-yl, benzo[b]furan-2-yl, [pyrazin-2-yl, quinazolin-2-yl, isothiazol-5-yl, isothiazol-3-yl, purin-8-yl and a substituted heterocycle where the substituents are selected from C<sub>1-4</sub> from C-14alkyl, perfluoro C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, hydroxy, halo, amido, nitro, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>dialkylamino, carboxy, C<sub>1-4</sub>alkoxycarbonyl, hydroxy or phenylC<sub>1-4</sub> alkylaminocarbonyl; or pharmaceutically acceptable salts thereof.

**[0018]** More particularly, in our opinion, some of the compounds of the foregoing formula containing a d-phenylalanine-proline-arginine motif should be effective in inhibiting the PAR-2 pathway and causing depigmentation. One particularly preferred compound which acts as a thrombin and trypsin inhibitor and is active in depigmenting mammalian skin is (S)-N-Methyl-D-phenylalanyl-N-[4-[aminoiminomethyl]amino]-1-(2-benzothiazolylcarbonyl)butyl]-L-prolineamide (Chemical Abstracts name) (hereinafter referred to as "Compound I"). We suggest that other compounds which are analogs or function similarly to Compound I and are set forth in U.S. Patent No. 5,523,308 may be active in the methods and compositions of this invention.

**[0019]** Other compounds that inhibit trypsin, such as serine protease inhibitors, and in particular, soybean trypsin inhibitor (STI) will also be useful in methods of this invention. Soybean, limabean and blackbean extracts, and other natural products made from these beans, such as, but not limited to, bean milk, bean paste, miso and the like, also serve to reduce pigmentation by this mechanism.

**[0020]** Additional sources of serine protease inhibitors may be extracted from the species belonging to the following plant families: Solanaceae (e.g., potato, tomato, tomatilla, and the like); Gramineae (e.g., rice, buckwheat, sorghum, wheat, barley, oats and the like); Cucurbitaceae (e.g., cucumbers, squash, gourd, luffa and the like); and, preferably, Leguminosae (e.g., beans, peas, lentils, peanuts, and the like).

**[0021]** While not willing to be bound by the following theory, we theorize that the compounds capable of affecting the pigmentation of the skin do so by interacting directly or indirectly with the keratinocyte PAR-2 or with its activating protease, and thereby affect melanogenesis, directly or indirectly. Possibly, the compounds of this invention induce, in the case of increased pigmentation or reduce, in the case of decreased pigmentation, the signal to transport melanosomes by melanocytes, or to receive melanosomes by keratinocytes in the skin.

**[0022]** Recently we have identified that the Bowman-Birk Inhibitor ("BBI"), a different group of legume-derived proteins, are also depigmenting agents.

**[0023]** While STI is a 21 KD protein with primarily trypsin inhibitory activity, the soybean-derived BBI is a smaller, 8 KD protein, which inhibits chymotrypsin and trypsin. Unlike STI, BBI does not have a Kunitz-type domain, suggesting different interactions with serine proteases. BBI is known for its ability to prevent carcinogenesis in numerous *in vivo* and *in vitro* models. In some animal carcinogenesis models BBI was found to have strong anti-inflammatory effects. BBI is more resistant than STI to heat-denaturation. For a review on BBI see Kennedy AR, Chemopreventive agents: protease inhibitors, Pharmacol Ther 78: 3, 167-209, Jun, 1998.

**[0024]** The compounds which are active in the compositions and methods of this invention may be delivered topically by any means known to those of skill in the art. If the delivery parameters of the topically active pharmaceutical or cosmetic agent so require, the topically active composition of this invention may preferably be further composed of a pharmaceutically or cosmetically acceptable vehicle capable of functioning as a delivery system to enable the penetration of the topically active agent into the skin.

**[0025]** One acceptable vehicle for topical delivery of some of the compositions of this invention, particularly proteins

such as trypsin and STI, may contain liposomes. The liposomes are more preferably non-ionic and contain a) glycerol dilaurate (preferably in an amount of between about 5% and about 70% by weight); b) compounds having the steroid backbone found in cholesterol (preferably in an amount of between about 5% and about 45% by weight); and c) one or more fatty acid ethers having from about 12 to about 18 carbon atoms (preferably in an amount of between about 5% and about 70% by weight collectively), wherein the constituent compounds of the liposomes are preferably in a ratio of about 37.5:12.5:33.3:16.7. Liposomes comprised of glycerol dilaurate / cholesterol/ polyoxyethylene -10-stearyl ether/polyoxyethylene-9-lauryl ether (GDL liposomes) are most preferred. Preferably the liposomes are present in an amount, based upon the total volume of the composition, of from about 10 mg/mL to about 100 mg/mL, and more preferably from about 20 mg/mL to about 50 mg/mL. A ratio of about 37.5:12.5:33.3:16.7 is most preferred. Suitable liposomes may preferably be prepared in accordance with the protocol set forth in Example 1, though other methods commonly used in the art are also acceptable.

**[0026]** The above described composition may be prepared by combining the desired components in a suitable container and mixing them under ambient conditions in any conventional high shear mixing means well known in the art for non-ionic liposomes preparations, such as those disclosed in Niemiec *et al.*, "Influence of Nonionic Liposomal Composition On Topical Delivery of Peptide Drugs Into Pilosebaceous Units: An In Vivo Study Using the Hamster Ear Model," 12 Pharm. Res. 1184-88 (1995) ("Niemiec"), which is incorporated by reference herein in its entirety. We have found that the presence of these liposomes in the compositions of this invention may enhance the depigmenting capabilities of some of the compositions of this invention.

**[0027]** Other preferable formulations may contain, for example, soybean milk or other liquid formulations derived directly from legumes or other suitable plant. For example, such a formulation may contain a large proportion of soybean milk, an emulsifier that maintains the physical stability of the soybean milk, and, optionally a chelating agent, preservatives, emollients, humectants and/or thickeners or gelling agents.

**[0028]** Oil-in-water emulsions, water-in-oil emulsions, solvent-based formulations and aqueous gels known to those of skill in the art may also be utilized as vehicles for the delivery of the compositions of this invention.

**[0029]** The source of active compound to be formulated will generally depend upon the particular form of the compound. Small organic molecules and peptidyl fragments can be chemically synthesized and provided in a pure form suitable for pharmaceutical/cosmetic usage. Products of natural extracts can be purified according to techniques known in the art. Recombinant sources of compounds are also available to those of ordinary skill in the art.

**[0030]** In alternative embodiments, the topically active pharmaceutical or cosmetic composition may be optionally combined with other ingredients such as moisturizers, cosmetic adjuvants, anti-oxidants, bleaching agents, tyrosinase inhibitors and other known depigmentation agents, surfactants, foaming agents, conditioners, humectants, fragrances, viscosifiers, buffering agents, preservatives, sunscreens and the like. The compositions of this invention may also contain active amounts of retinoids (i.e., compounds that bind to any members of the family of retinoid receptors), including, for example, tretinoin, retinol, esters of tretinoin and/or retinol and the like.

**[0031]** The topically active pharmaceutical or cosmetic composition should be applied in an amount effective to affect changes in the pigmentation of mammalian skin. As used herein "amount effective" shall mean an amount sufficient to cover the region of skin surface where a change in pigmentation is desired. Preferably, the composition is liberally applied to the skin surface such that, based upon a square cm of skin surface, from about 2  $\mu$ l/cm<sup>2</sup> to about 200  $\mu$ l/cm<sup>2</sup> of topically active agent is present when a change in pigmentation is desired. When using a thrombin and trypsin inhibitor such as Compound I or its analogs, whether synthetically- or naturally-derived in a formulation, such an active compound should be present in the amount of from about 0.0001% to about 15% by weight/volume of the composition. More preferably, it should be present in an amount from about 0.0005% to about 5% of the composition; most preferably, it should be present in an amount of from about 0.001 to about 1% of the composition. Of course, these ranges are suggested for the foregoing components. The lower set of ranges is intended to be efficacious for PAR-2 pathway agonists/antagonists and/or inhibitors having high therapeutic indices and which do not require significantly larger concentrations or doses to be effective in the methods of this invention. Such compounds may be synthetically- or naturally-derived.

**[0032]** Liquid derivatives and natural extracts made directly from plants or botanical sources may be employed in the compositions of this invention in a concentration (w/v) from about 1 to about 99%. Fractions of natural extracts and naturally-derived protease inhibitors such as STI may have a different preferred range, from about 0.01% to about 20% and, more preferably, from about 1% to about 10% of the composition. Of course, mixtures of the active agents of this invention may be combined and used together in the same formulation, or in serial applications of different formulations.

**[0033]** We have unexpectedly found that when topically active agents, such as PAR-2 agonists and/or inhibitors and trypsin and/or thrombin and/or tryptase and/or their inhibitors, are topically applied to an animal's skin, a significant change in pigmentation was achieved. Preferably, depigmenting agents (as well as other pigmentation-affecting agents of this invention) are applied to the skin of a mammal at a relatively high concentration and dose (from about 0.005% to about 1% for compounds having high therapeutic indices such as Compound I and related compounds; from about 20% to about 99% for liquid derivatives and extracts of botanical materials; and from about 1% to about 20% for fractions

of natural extracts and naturally-derived protease inhibitors such as STI or mixtures thereof) between one and two times daily for a period of time until the skin evidences a change in pigmentation. This may be for from about four to about ten weeks or more. Thereafter, once the change in pigmentation has been achieved, a lower concentration and dose (from about 0.00001% to about 0.005% for compounds having high therapeutic indices such as Compound I and related compounds; from about 10% to about 90% for liquid derivatives and extracts of botanical materials; and from about 0.01% to about 5% for fractions of natural extracts and naturally-derived protease inhibitors such as STI or mixtures thereof), of active ingredient may be applied on a less frequent time schedule, e.g., about once per day to about twice per week. The effects of the active agents of this invention are reversible, therefore, in order to maintain these effects, continuous application or administration should be performed. The invention illustratively disclosed herein suitably may be practiced in the absence of any component, ingredient, or step which is not specifically disclosed herein.

[0034] The invention illustratively disclosed herein suitably may be practiced in the absence of any component, ingredient, or step which is not specifically disclosed herein. Several examples are set forth below to further illustrate the nature of the invention and the manner of carrying it out, but do not serve to limit the scope of the methods and compositions of this invention.

#### Example 1: BBI Affects Pigmentation

[0035] In order to study the possible roles of BBI in pigmentation, an *in vitro* epidermal equivalent system containing melanocytes was used. The epidermal equivalent system used in this study is the MelanoDerm mel-300 system, available commercially from MatTek Co. of Ashland, MA. This system contains human normal melanocytes, together with normal, human-derived epidermal keratinocytes, derived from African-American foreskin. These cells have been cultured to form a multi-layered, highly differentiated model of the human epidermis. In the following examples, equivalents were treated with BBI (0.1%) for three days and samples were harvested on the fourth day after beginning of treatment. The harvested equivalents were first compared for their color without staining, following by histological examination with Fontana-Mason (F&M) staining, a stain known to those of skill in the art. F&M staining is a silver staining technique that clearly and cleanly marks melanins which have high silver nitrate reducing activity. Images of the stained sections were also captured for image analysis. At least three sections per equivalent, three equivalents per experiment were processed. Empire Images database 1.1 was used on a Gateway 2000 P5-100 computer (Media Cybernetics, Silver Springs, MD) for capturing images. Image Pro Plus version 3.0 was used for image analysis. Parameters measured were the surface area of silver deposits within melanocytes and the density luminosity of each pixel. A "pigmentation factor" was defined as the surface area of silver deposits divided by the total epidermal surface area. A value of one (100%) was assigned to untreated controls, and values of treatment groups were normalized to their relevant controls.

[0036] As shown in Figure 1, untreated mel-300 equivalents are visibly dark without any staining. BBI treated equivalents were lighter than these controls, demonstrating the ability of BBI to visually reduce pigmentation. Figure 2 shows the histological sections of these equivalents, following F&M staining. In this Figure, black areas represent melanin deposits within both melanocytes and keratinocytes. As shown in Figure 2, BBI treatment results in reduced melanin deposition both in the melanocytes and in the keratinocytes of the treated equivalents. Image analysis revealed that BBI treated equivalents have only 50.6% melanin deposits relative to controls.

#### Example 2: The depigmenting effect of BBI is dose-responsive.

[0037] Epidermal equivalents containing melanocytes as described in example 1 were treated with increasing concentrations of BBI, from 0.001% to 0.1%. Following the same experimental procedure described in example 1, the depigmenting effect of BBI was found to be dose-dependent. Figure 3 shows F&M stained sections of the treated equivalents, demonstrating the dose-response and the depigmenting effect of as low as 0.001% BBI. Computerized image analysis, shown in figure 4, quantifies this effect and further demonstrates its dose-responsive nature.

#### Example 3: *In vivo* demonstration of the depigmenting effect of BBI

[0038] A dark skin Yucatan microswine was treated with BBI, or STI, 1%, in PBS, with 20/mg/ml liposomes. Non-ionic liposomes preparations, such as those disclosed in Niemiec *et al.*, "Influence of Nonionic Liposomal Composition On Topical Delivery of Peptide Drugs Into Pilosebaceous Units: An In Vivo Study Using the Hamster Ear Model," 12 Pharm. Res. 1184-88 (1995) ("Niemiec"), which is incorporated by reference herein in its entirety, are well known in the art, and are described in JBP-430. We have found that the presence of these liposomes in the compositions of this invention may enhance the depigmenting capabilities of some of the compositions of this invention. GDL liposomes were prepared as set forth in Niemiec, *et al.*, above, with the exception of the following changes: the non-ionic liposomal formulation contained glycerol dilaurate (Emulsynt GDL, ISP Van Dyk)/cholesterol (Croda)/polyoxyethylene-10-stearyl ether (Brij76, ICI)/polyoxyethylene-9-lauryl ether, as at ratio of 37.5:12.5:33.3:16.7. Hepes buffer, 0.05M, pH 7.4 (Gibco-




BRL of Gaithersburg, MD) was used as the aqueous phase in the preparation of the liposomes.

**[0039]** The BBI, STI and liposome vehicle preparations were applied each onto two sites of the swine's flank, twice daily, five days per week, for eight weeks. After eight weeks of treatment, the application of either BBI or STI resulted in a visible lightening effect. Histological analysis of F&M stained skin sections from untreated and treated sites confirmed this observation. Figure 5 shows the F&M stained skin sections of the treated swine, demonstrating a dramatic reduction in pigment deposition in sites treated with BBI or STI. Computerized image analysis, shown in figure 6, quantifies this effect and further demonstrates the depigmenting effect of BBI.


## Claims

1. A method of effecting cosmetic changes in mammalian skin pigmentation comprising administering to a mammal a pigmentation-changing effective amount of a Bowman-Birk Inhibitor or of a natural extract containing a Bowman-Birk Inhibitor.
2. A method of depigmenting mammalian skin pigmentation comprising administering to a mammal a pigmentation-lightening effective amount of a Bowman-Birk Inhibitor or a natural extract containing a Bowman-Birk Inhibitor.
3. A method according to claim 2 wherein said Bowman-Birk Inhibitor is derived from one or more of the botanical families leguminosae, solanaceae, gramineae and cucurbitaceae.
4. A method according to claim 3 wherein said compound is derived from legumes.
5. A method according to claim 4 wherein said compound is derived from undenatured soybean extract.
6. A method according to claim 5 wherein said compound is derived from fractions of undenatured soybean extract.
7. A composition for effecting changes in mammalian skin pigmentation comprising a pigmentation-changing effective amount of a Bowman-Birk Inhibitor or of a natural extract containing a Bowman-Birk Inhibitor.
8. A composition for depigmenting mammalian skin pigmentation comprising a pigmentation-lightening effective amount of a Bowman-Birk Inhibitor or of a natural extract containing a Bowman-Birk Inhibitor.
9. A composition according to claim 8 wherein said Bowman-Birk Inhibitor is derived from one or more of the botanical families leguminosae, solanaceae, gramineae and cucurbitaceae.
10. A composition according to claim 9 wherein said compound is derived from undenatured soybean extract.


**Figure 1**




**Figure 2**



**Figure 3**




**Figure 4**




**Figure 5**

**The Soybean derived proteins BBI and STI reduce  
pigmentation in the Yucatan Swine**



**Figure 6**

**The Soybean derived proteins BBI and STI reduce pigmentation in the Yucatan swine**



(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 077 063 A3**

(12)

**EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:  
**12.02.2003 Bulletin 2003/07**

(51) Int Cl.7: **A61K 7/48**

(43) Date of publication A2:  
**21.02.2001 Bulletin 2001/08**

(21) Application number: **00306352.6**

(22) Date of filing: **26.07.2000**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(72) Inventors:  
• **Seiberg, Miri**  
**Princeton, NJ 08540 (US)**  
• **Shapiro, Stanley S.**  
**Livingston, NJ 07039 (US)**

(30) Priority: **27.07.1999 US 361429**

(71) Applicant: **JOHNSON & JOHNSON CONSUMER  
COMPANIES, INC.**  
**Skillman, NJ 08558 (US)**

(74) Representative: **Fisher, Adrian John**  
**CARPMAELS & RANSFORD**  
**43 Bloomsbury Square**  
**London WC1A 2RA (GB)**

(54) **Methods for treating skin pigmentation**

(57) This invention relates to methods and compositions for bringing about changes in skin pigmentation. More particularly, this invention relates to compounds which affect melanogenesis and can be used as depigmenting agents or as agents for darkening skin utilizing the PAR-2 pathway.

**EP 1 077 063 A3**





European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 00 30 6352 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	DATABASE WPI Week 199231 Derwent Publications Ltd., London, GB; AN 1992-253484 XP002224354 & JP 04 169514 A (SHISEIDO), 17 June 1992 (1992-06-17) * abstract *	1-10	A61K7/48
D,X	WO 99 04752 A (JOHNSON & JOHNSON CONSUMER COMPANIES) 4 February 1999 (1999-02-04) * claims 11,26,35,40 *	1,2,5-8,10	
X	WO 91 07166 A (WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION) 30 May 1991 (1991-05-30) * claims 1-24; example 2 *	1-10	
A	WO 99 09065 A (EBERHARD-KARLS-UNIVERSITÄT TÜBINGEN) 25 February 1999 (1999-02-25) * claims 1-12,17 *	1-10	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K
<p><b>INCOMPLETE SEARCH</b></p> <p>The Search Division considers that the present application, or one or more of its claims, does/does not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely:</p> <p>Claims searched incompletely:</p> <p>Claims not searched:</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		10 December 2002	Willekens, G
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/82 (P04C07)



European Patent  
Office

INCOMPLETE SEARCH  
SHEET C

Application Number  
EP 00 30 6352

Claim(s) searched completely:  
5,6,10

Claim(s) searched incompletely:  
1-4,7-9

Reason for the limitation of the search:

Present claims 1-4,7-9 relate to an extremely large number of possible compounds. Support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to these compounds referring to Bowman-Birk Inhibitors derived from soybean according to claims 5,6, and 10, the compound described on page 11, lines 14-16, viz.  
(S)-N-methyl-D-phenylalanyl-N-4-((aminoiminomethyl)amino)-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide, or the compounds according to page 12, lines 9-16.



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 00 30 6352

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
T	FR 2 811 226 A (CLARINS LABORATOIRES) 11 January 2002 (2002-01-11) * claims 1-10 * -----	1-10	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)

EPO FORM 1503 03.92 (P04C10)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 30 6352

This annex lists the patent/family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file.  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

10-12-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
JP 4169514	A	17-06-1992	JP 3032566 B2	17-04-2000
WO 9904752	A	04-02-1999	AU 8756698 A	16-02-1999
			BR 9806118 A	31-08-1999
			CN 1234735 T	10-11-1999
			EP 0948308 A1	13-10-1999
			HU 0000216 A2	28-06-2000
			JP 2001502360 T	20-02-2001
			PL 333284 A1	22-11-1999
			WO 9904752 A2	04-02-1999
			ZA 9806679 A	27-01-2000
			US 6323219 B1	27-11-2001
			US 2002065300 A1	30-05-2002
WO 9107166	A	30-05-1991	WO 9107166 A1	30-05-1991
WO 9909065	A	25-02-1999	DE 19735587 A1	04-03-1999
			AU 744184 B2	14-02-2002
			AU 8854298 A	08-03-1999
			CA 2301717 A1	25-02-1999
			WO 9909065 A1	25-02-1999
			EP 1003786 A1	31-05-2000
FR 2811226	A	11-01-2002	FR 2811226 A1	11-01-2002

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**